Open Access

PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues

  • Simone Däpp1,
  • Cristina Müller1,
  • Elisa García Garayoa1,
  • Peter Bläuenstein1,
  • Veronique Maes2,
  • Luc Brans2,
  • Dirk A Tourwé2 and
  • Roger Schibli1, 3Email author
EJNMMI Research20122:24

DOI: 10.1186/2191-219X-2-24

Received: 25 February 2012

Accepted: 9 June 2012

Published: 9 June 2012



Radiolabelled bombesin (BN) conjugates are promising radiotracers for imaging and therapy of breast and prostate tumours, in which BN2/gastrin-releasing peptide receptors are overexpressed. We describe the influence of the specific activity of a 177Lu-DOTA-PEG5k-Lys-B analogue on its therapeutic efficacy and compare it with its non-PEGylated counterpart.


Derivatisation of a stabilised DOTA-BN(7–14)[Cha13,Nle14] analogue with a linear PEG molecule of 5 kDa (PEG5k) was performed by PEGylation of the ϵ-amino group of a β3hLys-βAla-βAla spacer between the BN sequence and the DOTA chelator. The non-PEGylated and the PEGylated analogues were radiolabelled with 177Lu. In vitro evaluation was performed in human prostate carcinoma PC-3 cells, and in vivo studies were carried out in nude mice bearing PC-3 tumour xenografts. Different specific activities of the PEGylated BN analogue and various dose regimens were evaluated concerning their therapeutic efficacy.


The specificity and the binding affinity of the BN analogue for BN2/GRP receptors were only slightly reduced by PEGylation. In vitro binding kinetics of the PEGylated analogue was slower since steady-state condition was reached after 4 h. PEGylation improved the stability of BN conjugate in vitro in human plasma by a factor of 5.6. The non-PEGylated BN analogue showed favourable pharmacokinetics already, i.e. fast blood clearance and renal excretion, but PEGylation improved the in vivo behaviour further. One hour after injection, the tumour uptake of the PEG5k-BN derivative was higher compared with that of the non-PEGylated analogue (3.43 ± 0.63% vs. 1.88 ± 0.4% ID/g). Moreover, the increased tumour retention resulted in a twofold higher tumour accumulation at 24 h p.i., and increased tumour-to-non-target ratios (tumour-to-kidney, 0.6 vs. 0.4; tumour-to-liver, 8.8 vs. 5.9, 24 h p.i.). In the therapy study, both 177Lu-labelled BN analogues significantly inhibited tumour growth. The therapeutic efficacy was highest for the PEGylated derivative of high specific activity administered in two fractions (2 × 20 MBq = 40 MBq) at day 0 and day 7 (73% tumour growth inhibition, 3 weeks after therapy).


PEGylation and increasing the specific activity enhance the pharmacokinetic properties of a 177Lu-labelled BN-based radiopharmaceutical and provide a protocol for targeted radionuclide therapy with a beneficial anti-tumour effectiveness and a favourable risk-profile at the same time.


Gastrin-releasing peptide Prostate cancer 177Lu Radionuclide therapy PEGylation


Prostate and breast cancers are the most frequently diagnosed forms of cancer in the USA. Especially in addressing metastatic and small-volume diseases, it is essential to investigate, alongside conventional therapies, alternative treatments, such as peptide receptor radionuclide therapy (PRRT). The fact that certain tumour types overexpress, receptors for peptide-hormones provide the basis for successful use of radiolabelled peptide analogues as tumour tracers in nuclear medicine. The mammalian gastrin-releasing peptide receptor (BN2/GRP) [1, 2] is particularly overexpressed in several human tumours, including prostate, breast and small-cell lung cancers [35]. The tetradecapeptide bombesin (BN) shows high binding affinity for these BN2/GRP receptors. Using BN conjugates for specific delivery of radionuclides into the above-mentioned tumours is therefore a promising strategy for diagnostic and therapeutic purposes.

BN analogues, however, present certain problems regarding therapy. They show poor enzymatic stability in vivo, which might prevent sufficient localisation at the target site. Furthermore, high accumulation and retention in healthy organs, which express the BN2/GRP receptor, increase the risk of side effects. Moreover, kidney toxicity, which was observed and investigated in PRRT with somatostatin analogues in clinical studies [68], may also hold true for BN analogues. Finally, several side effects were elicited from intravenous (i.v.) injection of BN agonists in humans. Therefore, a high specific activity of the radiolabelled BN agonist may be important in minimising such undesired effects.

Until now, the research has focused on optimising BN conjugates for nuclear imaging of cancer which overexpresses BN2/GRP receptors. Different BN analogues were labelled with diagnostic single-photon emission computed tomography (SPECT) and positron emission tomography (PET) radionuclides, such as 111In [911], 99mTc [1215], 18 F [1618], 68 Ga [19, 20] and 64Cu [21], and were evaluated in preclinical studies for their ability to detect BN2/GRP receptor-positive lesions. However, only a few radiolabelled BN analogues have been tested in clinics on their diagnostic potential [20, 22]. So far, only three BN analogues, AMBA, DOTA-8-AOC-BN(7–14)NH2 and DOTA-PESIN, have been rated in preclinical investigations on their potential for radionuclide therapy [2325]. They were radiolabelled with 177Lu (beta-emitter, Eβ −max 0.497 MeV, half-life of 6.7 days) or with 213Bi (alpha-emitter, Eβ −max 1.423 MeV, Eαmax 5.982 MeV, half-life of 45.6 min). The in vitro and in vivo evaluations of our 177Lu-DOTA-Lys-BN analogue (DOTA-β3hLys-βAla-βAla-Gln7-Trp8-Ala9-Val10-Gly11-His12-Cha13-Nle14-NH2) showed pharmacokinetic properties which are comparable to that reported for the above-mentioned BN analogues. Therefore, we wanted to improve the radiotherapy-relevant characteristics further by PEGylating 177Lu-DOTA-Lys-BN.

Our preclinical study with a series of 99mTc(CO)3-labelled PEGylated BN analogues showed that PEGylation is an effective strategy to improve the therapy-relevant characteristics, which include higher tumour uptake, improved tumour retention and lower uptake into non-target tissue. The PEG entity of 5 kDa was established as the optimal PEG size because it improved these features best [26].

The BN analogues of the current study were therefore based on one of our stabilised analogues (Gln7-Trp8-Ala9-Val10-Gly11-His12-Cha13-Nle14-NH2) containing a β3hLys-βAla-βAla spacer (Figure 1) [14]. The peptide was equipped with a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator to provide the analogue DOTA-β3hLys-βAla-βAla-Gln7-Trp8-Ala9-Val10-Gly11-His12-Cha13-Nle14-NH2 (referred to as DOTA-Lys-BN, Figure 1a). We hypothesised that PEGylating this DOTA-Lys-BN would lead to the same favourable characteristics seen with PEGylated 99mTc-based BN analogues. Derivatisation of the DOTA-Lys-BN analogue with a linear PEG molecule of 5 kDa (PEG5k) was performed by PEGylation of the ϵ-amino group of the lysine residue. The resulting PEGylated BN (referred to as DOTA-PEG5k-Lys-BN, Figure 1b) as well as the DOTA-Lys-BN were then radiolabelled with 177Lu. We chose this radionuclide because it is currently used together with 90Y for PRRT with somatostatin analogues on a routine basis in clinics [27, 28] and because it proved to be less problematic concerning kidney toxicity in comparison with the 90Y-radiolabelled somatostatin analogue [8, 27]. Furthermore, application of 177Lu allows imaging and PRRT at the same time owing to γ-ray emissions of suitable energy for SPECT, which enables dosimetry calculations and therapy monitoring [29].
Figure 1

Chemical structures of (a) DOTA-Lys-BN and (b) DOTA-PEG 5k -Lys-BN analogues.

In the current study, the new 177Lu-labelled DOTA-Lys-BN and DOTA-PEG5k-Lys-BN analogues were tested in vitro in human prostate carcinoma PC-3 cells and in PC-3 tumour bearing mice. They were compared in order to evaluate the effect of PEGylation on in vivo pharmacokinetics and their therapeutic effectiveness. Apart from looking at the anti-tumour efficacy, we also investigated the optimal risk-benefit profile by varying the specific activity of the radiolabelled DOTA-PEG5k-Lys-BN analogue and assessed the efficacy of PRRT by varying the number and the interval of the 177Lu-DOTA-PEG5k-BN doses. For an estimation of potential kidney toxicity, the renal function was monitored with quantitative 99mTc-DMSA scintigraphy.


Sources of materials, equipment, peptide synthesis and PEGylation are presented in Additional file 1.

Statistical analysis

All data are presented as mean ± SD. The in vivo data were statistically analysed with a t test (Microsoft Excel software). All analyses were 2-tailed and considered as type 3 (two-sample unequal variance); P < 0.05 was considered statistically significant.

177Lu labelling of the DOTA-lys-BN and DOTA-PEG5k-lys-BN analogues

For high specific activity labelling, 16 μl of approximately 400 MBq 177LuCl3 (714.3 GBq/μmol) were added to a mixture of 20 μl ammonium acetate solution (0.5 M, pH 7.5), 84 μl HCl (0.04 M), 5 μl ascorbic acid solution (0.05 M) and 5.6 nmol of BN analogue (high specific, 66 MBq/nmol peptide). The final solution (pH 4.5) was heated at 75 °C for 15 min (Additional file 1: Figure S7). For the 177Lu-labelled BN analogues of low specific activity (6.6 MBq/nmol peptide), unlabelled BN analogue was added to the high specific labelling solution to reach the respective concentration.

Metabolic stability in human plasma

The labelled analogues were incubated with human plasma (final concentration, 10 MBq/0.6 ml) at 37 °C for various time intervals up to 12 days. After incubation, proteins were precipitated with acetonitrile/ethanol (1:1) and TFA (0.1%) and then centrifuged. The supernatant was analysed with RP-high-performance liquid chromatography (HPLC) equipped with a radioactivity detector. The radioactivity chromatograms showed different peaks which corresponded to the intact peptide and the different degradation products. The experiments were performed two times.

Internalisation and externalisation studies

For internalisation, PC-3 cells at confluence were placed in six-well plates and left to attach overnight. Cells were incubated with the labelled analogues (4 kBq) in culture medium for 0.5, 1, 2, 4 and 24 h at 37 °C. Non-specific binding was determined with 1 μM unlabelled BN(1–14). After the different incubation times, cells were twice washed with cold phosphate buffered saline (PBS) to discard unbound peptide. Surface-bound activity was removed by two 5-min acid washes (50 mM glycin-HCl, 100 mM NaCl, pH 2.8). Afterwards, the cells were washed with cold PBS, and lysed with 1 N NaOH twice. Surface-bound and internalised radioactivities were measured in the gamma counter.

For externalisation, PC-3 cells were incubated with the labelled analogues (60 kBq) in culture medium at 37 °C for 1 h. After incubation, the supernatant was discarded, and the cells were twice washed with cold PBS. The cells were then incubated again at 37 °C in culture medium for 0.5, 1, 2.5, 5 and 24 h. At each time point, the supernatant was collected, the cells twice washed with cold PBS and lysed with 1 N NaOH. The supernatant (released radioactivity) and the cells (bound/internalised radioactivity) were measured in the gamma counter. All experiments were carried out two to three times in triplicate.

Biodistribution studies

All animal experiments were conducted in compliance with the Swiss animal protection laws and with the ethical principles and guidelines for scientific animal experimentation established by the Swiss Academy of Natural Sciences. Biodistribution studies were performed with 6- to 8-week-old female CD-1 nu/nu mice (20 to 25 g) purchased from Charles River Laboratories (Sulzfeld, Germany). For the induction of tumour xenografts, each mouse received subcutaneously 8 × 106 PC-3 cells in 150 μl culture medium without supplements. The tumours were allowed to grow for at least 3 weeks. On the day of the experiment, the mice (3 to 6 per group) received the radioactive conjugates intravenously. For the biodistribution studies, the mice were injected with different specific activities of the radiolabelled BN analogues (low specific, 6.6 MBq/nmol peptide; high specific, 66 MBq/nmol peptide). Receptor-blocking studies were performed using 100 μg of unlabelled BN(1–14) co-injected with the corresponding radiolabelled BN analogue. At 1, 4 and 24 h post injection (p.i.), the animals were euthanised and dissected. Blood, tumours and various healthy tissues and organs were collected, weighed and examined for radioactivity. Results are expressed as percentage of injected dose per gram of tissue (% ID/g).

Dose calculation

The absorbed doses to PC-3 tumours and critical organs were calculated from the biodistribution studies (1 MBq/0.1 ml; 0.3 or 3.0 nmol peptide; n = 3 per group). Under the assumption of rapid accumulation (uptake at 0 h p.i. corresponds to the uptake at 1 h p.i.), the cumulative radioactivity in each tissue was calculated (MBq/h) taking biologic elimination and physical decay into account up to 24 h p.i. and afterwards only physical decay up to 400 h p.i. The absorbed tumour doses of the mouse experiments were extrapolated from the sphere model doses which were calculated by using the software OLINDA (OLINDA/EXM1.0, Vanderbilt University, Nashville, TN, USA). The S values for all other tissues of mice were taken from E Larsson [30]. The absorbed dose (milligray per mega-Bequerel) was calculated by multiplying the area under the curve (AUC) (h; normalised to 1 MBq ID) with the S value (mGy/(MBqs)). The dose (in Gy) was calculated by multiplying the absorbed dose (mGy/MBq) with the amount of radioactivity injected (20 MBq). The AUC-estimate for an adult male was obtained by multiplying the AUC of the mice (MBq/h) with a factor consisting of (total body weightmouse/total body weightadult male) × organ weightadult male. The subsequent dose calculation was performed using the adult male model of the software OLINDA.

Therapy studies

Therapy studies were conducted in mice bearing PC-3 xenografts. The tumour was assumed to be an ellipsoid, and its volume was calculated with the formula V t = ( π / 6 ) L W 2 where L represents the longest dimension and W the shortest dimension of the tumour. Two weeks post PC-3 inoculation, i.e. the day of the first injection (day 0), the tumours had an average volume of 85 mm3. The animals were divided into six groups of six mice (Table 1). The control group received an i.v. injection of PBS only (group A). Another group was injected with unlabelled DOTA-PEG5k-Lys-BN at a peptide amount of 3.0 nmol (group B). The treated mice received two equal doses of 20 MBq i.v. either of 177Lu-DOTA-PEG5k-Lys-BN (groups C to E) or of 177Lu-DOTA-Lys-BN (group F) at a peptide amount of 0.3 or 3.0 nmol. The injections were performed either at days 0 and 14 or at days 0 and 7 (Table 1). Body weight and tumour volume of all mice were quantified 3 times per week. The relative volume of tumours V r was defined as V r = V t /V 0, where V t was the measurement at time t (days after the first injection), and V 0 was the measurement at day 0. If a tumour disappeared, V t was set to 0. Mice were removed from the study promptly upon fulfilling one or both of the following criteria: a tumour volume of  ≥ 1.5 cm2 or total body weight loss of ≥ 15%. Upon euthanasia, tumours were collected and embedded in TissueTek (Sakura Finetek, USA Inc., Torrance, CA, USA) and frozen for autoradiography.
Table 1

Therapy protocol: classification of therapy groups and specification of administration of the BN analogues

Therapy groups

BN analogues

Dose and peptide amount

Injection time

Mice with PC-3 tumour xenografts



2 × 100 μl

Days 0 and 14



2 × 3.0 nmol

Days 0 and 14



2 × 20 MBq/3.0 nmol each

Days 0 and 14



2 × 20 MBq/0.3 nmol each

Days 0 and 14



2 × 20 MBq/0.3 nmol each

Days 0 and 7



2 × 20 MBq/0.3 nmol each

Days 0 and 14

Mice without PC-3 tumour xenografts



2 × 100 μl

Days 0 and 14




2 × 20 MBq/0.3 nmol each

Days 0 and 14




2 × 20 MBq/3.0 nmol each

Days 0 and 14

99mTc-DMSA SPECT/CT imaging studies

Three groups of four mice each (groups G to I, Table 1), which were not xenografted with PC-3 cells, were included in the therapy study for 99mTc-DMSA tests. An untreated control group of mice (group G), a treated group receiving two doses of the 177Lu-DOTA-PEG5k-Lys-BN analogue at high specific activity (group H) and a treated group of mice getting two doses of the 177Lu-DOTA-PEG5k-Lys-BN analogue with low specific activity (group I). 99mTc-DMSA scans with SPECT/computed tomography (CT) were obtained 43, 71 and 111 days after therapy, 2 h after i.v. injection of about 30 MBq 99mTc-DMSA. SPECT scans were acquired with anaesthetised mice during 20 min using 15 projections/min. The images were obtained on an X-SPECT-system (Gamma Medica, Inc., Northridge, CA, USA) equipped with a single head SPECT device and a CT device. SPECT data were acquired and reconstructed with LumaGEM (version 5.407, Gamma Medica, Northridge, CA, USA). CT data were acquired with an X-ray CT-system (Gamma Medica) and reconstructed with the software CoBRA (version 4.5.1, Falls Church, VA, USA). SPECT and CT data were combined with the software IDL Virtual Machine (version 6.0, Exelis Visual Information Solutions, Inc., McLean, VA, USA). The images were generated with Amira (version 4.0). Quantification of the amount of radioactivity in a volume of interest over the kidneys was performed with Amira (version 4.0, San Diego, CA, USA). Detected counts in the volume of interest were normalised to 1 MBq ID.

Results and discussion


In vitro evaluation

The PEGylation of the DOTA-Lys-BN analogue (Additional file 1: Figure S7) as well as the results of the log D and IC50 determination are presented in Additional file 1. PEGylation resulted in a slightly increased hydrophilicity of the analogue and in an eightfold higher IC50 value compared with that of the non-PEGylated analogue (15.96 ± 4.42 nM vs. 2.03 ± 0.42 nM). The 177Lu-DOTA-Lys-BN was rapidly degraded by proteases in human plasma. After 5 days of incubation, it was almost entirely metabolised, and only 13.8 ± 5.7% remained intact. PEGylation resulted in a marked increase in protease stability; 51.8 ± 0.9% of 177Lu-DOTA-PEG5k-Lys-BN still remained intact after 5 days of incubation and 43.7 ± 0.5% after 11 days. Moreover, the half-life of 177Lu-DOTA-Lys-BN in human plasma was 1.2 ± 0.3 days, whereas the half-life of 177Lu-DOTA-PEG5k-Lys-BN was 6.7 ± 1.4 days (Figure 2).
Figure 2

Metabolic stability of 177 Lu-DOTA-Lys-BN and 177 Lu-DOTA-PEG 5k -Lys-BN in human plasma.

177Lu-DOTA-Lys-BN internalised rapidly into PC-3 cells and reached its maximum within the first hour of incubation (approximately 30%/106 cells). The PEGylated analogue showed a significantly lower and slower internalisation into PC-3 cells. After incubation for 4 h, the internalised fraction was 3.3 ± 1.2%. Externalisation studies revealed 63.1 ± 4.0% of the internalised 177Lu-DOTA-Lys-BN externalised within the first 2.5 h. After 24 h, only 13.5 ± 7.2% of the internalised fraction was found in the cells. In contrast, the externalisation of the PEGylated analogue was slower (24.2 ± 1.3% after 24 h).

Biodistribution studies

The effect of PEGylation was tested in vivo in mice with PC-3 tumour xenografts performed with BN conjugates at an injected peptide amount of 0.075 nmol (Table 2). The highest tumour uptake of 177Lu-DOTA-Lys-BN (1.88% ID/g) and 177Lu-DOTA-PEG5k-Lys-BN (3.43% ID/g) was found 1 h p.i., the latter being significantly higher. Thus, the enhanced enzymatic stability induced by PEGylation compensated for the lower receptor affinity of DOTA-PEG5k-Lys-BN. Furthermore, the tumour washout was slightly slower for the PEGylated analogue. Thus, 1.04% ID/g was found for the 177Lu-DOTA-PEG5k-Lys-BN 24 h p.i., whereas only 0.54% ID/g of 177Lu-DOTA-Lys-BN remained in the tumour. At 1 h p.i., both analogues showed their highest uptake in the pancreas, which expresses GRP receptors (8.68% ID/g and 9.62% ID/g for 177Lu-DOTA-Lys-BN and 177Lu-DOTA-PEG5k-Lys-BN, respectively). The liver uptake of both 177Lu-DOTA-Lys-BN and 177Lu-DOTA-PEG5k-Lys-BN was low (0.26% ID/g and 0.57% ID/g at 1 h p.i., respectively). Kidney accumulation was higher for the 177Lu-DOTA-PEG5k-Lys-BN in comparison with that of the non-PEGylated analogue at 1 h p.i. (4.89% ID/g vs. 2.86% ID/g, respectively). The renal clearance, however, was fast for both analogues (1.84% ID/g vs. 1.41% ID/g at 24 h p.i., respectively). The conjugation of a PEG5k entity resulted in a significantly longer blood circulation during 1 h p.i., but both derivatives were completely cleared from blood within 24 h p.i. (Table 2).
Table 2

Biodistribution (0.3 MBq/0.075 nmol) of 177 Lu-labelled BN analogues in nude mice bearing PC-3 tumour



177Lu-DOTA-PEG 5k-Lys-BN


177Lu-DOTA-PEG 5k-Lys-BN


1 h p.i.

24 h p.i.

1 h p.i.

24 h p.i.

1 h p.i. blocked

1 h p.i. blocked


0.24 ± 0.07

0.00 ± 0.00

1.54 ± 0.33*

0.01 ± 0.00*



0.14 ± 0.06

0.01 ± 0.01

0.49 ± 0.05

0.04 ± 0.01



0.36 ± 0.08

0.02 ± 0.01

1.10 ± 0.15

0.13 ± 0.02



0.42 ± 0.12

0.18 ± 0.04

0.72 ± 0.02

0.19 ± 0.03



2.86 ± 0.63

1.41 ± 0.14

4.89 ± 1.33

1.84 ± 0.52



8.68 ± 1.95

4.27 ± 0.85

9.62 ± 2.39

4.87 ± 1.11

0.49 ± 0.22**

0.98 ± 0.59*


0.72 ± 0.19

0.10 ± 0.02

1.12 ± 0.15

0.22 ± 0.07


Small intestine

1.38 ± 0.41

0.16 ± 0.03

1.18 ± 0.22

0.17 ± 0.12



1.64 ± 0.40

0.36 ± 0.09

2.19 ± 0.91

0.45 ± 0.21

0.36 ± 0.07**

0.66 ± 0.14


0.26 ± 0.09

0.09 ± 0.02

0.57 ± 0.04

0.16 ± 0.09



0.20 ± 0.24

0.01 ± 0.00

0.31 ± 0.06

0.42 ± 0.69



0.36 ± 0.24

0.02 ± 0.01

0.70 ± 0.06

0.58 ± 0.44



1.88 ± 0.47

0.54 ± 0.30

3.43 ± 0.63*

1.04 ± 0.04

0.55 ± 0.03*

1.02 ± 0.34**

*P < 0.05; **P < 0.01. Data in percentage of injected dose per gram of tissue (%ID/g), expressed as mean ± SD at 1 and 24 h p.i. (n = 3 to 4).

Specificity for GRP receptors could be demonstrated by a co-administration of non-radioactive BN(1–14). Thus, only the uptake in the receptor-expressing tissues such as the pancreas, colon and tumour was markedly reduced (>70%), whereas the inhibition was slightly less effective for the PEGylated BN analogue (Table 2).

The tumour-to-non-target ratios were similar for both derivatives. The initial longer circulation time of 177Lu-DOTA-PEG5k-Lys-BN, however, resulted in lower tumour-to-blood ratios at 1 and 4 h p.i. compared with that of the non-PEGylated compound. 177Lu-DOTA-PEG5k-Lys-BN showed a twofold increase in the tumour-to-pancreas ratio at all time points and in tumour-to-kidney and tumour-to-liver ratios at 24 h p.i. (Figure 3).
Figure 3

Tumour-to-non-target ratios. (a) Tumour-to-blood, (b) tumour-to-pancreas, (c) tumour-to-kidney and (d) tumour-to-liver ratios.

In additional biodistribution studies, two ligand doses of the 177Lu-DOTA-PEG5k-Lys-BN at a peptide amount corresponding to the amount that was injected in the therapy studies (high specific, 0.3 nmol; or low specific, 3.0 nmol peptide injected per mouse) were administered. This showed that the uptake in the receptor-expressing tissues such as the pancreas and colon was markedly reduced by applying a high amount of PEGylated peptide (3.0 nmol). The tumour uptake was also reduced by 29% and 42% at 1 h p.i. and 24 h p.i. after injection of a high amount of peptide (Figure 4, Table 3). In comparison, the tumour-to-blood, tumour-to-liver, tumour-to-kidney and tumour-to-muscle ratios were approximately twofold higher at all time points if 177Lu-DOTA-PEG5k-Lys-BN was injected at a low molar amount of peptide (0.3 nmol). The only ratios which revealed a higher value with a high amount of peptide (3.0 nmol) were the tumour-to-pancreas ratios (Table 3).
Figure 4

Influence of the amount of injected peptide on the biodistribution of 177 Lu-DOTA-PEG 5k -Lys-BN.

Table 3

Biodistribution (1 MBq/0.3 or 3.0 nmol) of 177 Lu-DOTA-PEG 5k -Lys-BN analogue in nude mice bearing PC-3 tumours


177Lu-DOTA-PEG 5k-Lys-BN


1 h p.i.

24 h p.i.


0.3 nmol

3.0 nmol

0.3 nmol

3.0 nmol


0.51 ± 0.09

0.77 ± 0.11*

0.02 ± 0.00

0.02 ± 0.00


0.22 ± 0.05

0.31 ± 0.09

0.04 ± 0.01

0.05 ± 0.01


0.92 ± 0.59

2.03 ± 1.64

0.44 ± 0.32

0.58 ± 0.36


0.45 ± 0.11

0.39 ± 0.05

0.40 ± 0.06

0.21 ± 0.04


3.11 ± 0.42

3.92 ± 0.59

1.59 ± 0.42

2.12 ± 0.21


4.65 ± 0.18**

1.45 ± 0.18

3.72 ± 0.98*

0.90 ± 0.26


0.42 ± 0.09

0.89 ± 0.65

0.16 ± 0.03

0.14 ± 0.10

Small intestine

0.55 ± 0.02

0.78 ± 0.39

0.20 ± 0.04*

0.10 ± 0.02


0.79 ± 0.14

0.59 ± 0.10

0.31 ± 0.08*

0.11 ± 0.03


0.50 ± 0.06

0.64 ± 0.07

0.51 ± 0.05

0.46 ± 0.02


0.17 ± 0.03

0.20 ± 0.05

0.02 ± 0.01

0.02 ± 0.00


0.21 ± 0.03

0.31 ± 0.03

0.23 ± 0.03

0.22 ± 0.03


2.06 ± 0.41*

1.47 ± 0.42

1.14 ± 0.10

0.66 ± 0.26


4.08 ± 0.54

1.89 ± 0.42

62.46 ± 3.58

36.24 ± 13.73


4.11 ± 0.67

2.28 ± 0.60

2.78 ± 0.21

1.47 ± 0.56


0.67 ± 0.14

0.38 ± 0.13

0.62 ± 0.07

0.33 ± 0.16


12.26 ± 4.01

7.20 ± 0.90

55.89 ± 32.86

27.27 ± 11.92


0.44 ± 0.08

1.01 ± 0.23

0.28 ± 0.08

0.62 ± 0.22

*P < 0.05.; **P < 0.001. Data in percentage of injected dose per gram of tissue (%ID/g), expressed as mean ± SD at 1 and 24 h p.i. (n = 3).

Dose calculation

After applying 177Lu-DOTA-PEG5k-Lys-BN at a low molar amount of peptide (0.3 nmol) in a single dose, the absorbed doses were calculated to be 0.36 Gy/MBq for the murine kidney, 0.002 Gy/MBq for the blood, 0.02 Gy/MBq for the pancreas and 0.19 Gy/MBq for the tumour. After the application of 177Lu-DOTA-PEG5k-Lys-BN at a high amount of peptide (3.0 nmol), however, the absorbed doses to the murine kidney, blood, pancreas and tumour were calculated to be 0.50, 0.002, 0.006 and 0.11 Gy/MBq, respectively. The estimate for an adult male resulted in absorbed doses to the kidney, blood and pancreas of 9.4, 0.4 and 21.3 Gy/GBq (0.3 nmol) and 12.3, 0.4 and 5.2 Gy/GBq (3.0 nmol), respectively.

Therapy studies

The therapy study was performed according to the protocol shown in Table 1. In total, 48 mice were included and divided into six groups of mice bearing PC-3 tumours (groups A to F; n = 6) and three additional groups of mice without tumours (groups G to I; n = 4). All groups of mice which received the 177Lu-labelled BN analogues (C to F) clearly showed a reduction of tumour growth in comparison with groups A and B which received only PBS or unlabelled BN analogue. The treatment with the non-PEGylated 177Lu-labelled BN analogue (0.3 nmol; group F) significantly decreased the PC-3 tumour growth rate with respect to that of group A and exhibited an inhibition of 53% 3 weeks after the first dose (Figures 5 and 6). The tumour growth inhibition was higher (63%) with the 177Lu-DOTA-PEG5k-Lys-BN analogue of high specific activity (group D). However, the 177Lu-DOTA-PEG5k-Lys-BN analogue of low specific activity (group C) exhibited only an inhibition of 36%. The most effective tumour growth inhibition of 73% (3 weeks after the first dose) was observed when the second dose of the PEGylated BN analogue of high specific activity was applied 7 days after the first dose (group E; Figure 6). Mice of group B did not show an increased tumour growth with respect to group A (Figure 5), although BN agonists are known to have mitogenic characteristics.
Figure 5

Therapeutic effect of 177 Lu-DOTA-PEG 5k -Lys-BN in mice with PC-3 tumour xenografts. The graph shows the comparison of treatment with high specific activity (2 × 20 MBq/0.3 nmol peptide each; group D) and low specific activity (2 × 20 MBq/3.0 nmol peptide each; group C). Besides, it shows the effect of unlabelled DOTA-PEG5k-Lys-BN (2 × 3.0 nmol peptide; group B) on tumour growth. Data are expressed as the volume of tumour relative to the volume in the same animal immediately before the first injection (mean ± SD of six animals).

Figure 6

Therapeutic effect of the 177 Lu-labelled BN analogues. Peptides were labelled with high specific activity (2 × 20 MBq/0.3 nmol peptide each) and injected in mice with PC-3 tumour xenografts. The graph shows the comparison of treatment with the PEGylated (group D) and the non-PEGylated (group F) 177Lu-labelled BN analogues. Besides, it shows the influence of timing the second dose (second dose at day 7 vs. day 14; group E vs. group D). Data are expressed as the volume of tumour relative to the volume in the same animal immediately before the first injection (mean ± SD of six animals).

99m Tc-DMSA SPECT/CT imaging studies

Forty-three days after therapy, the renal 99mTc-DMSA uptake of the treated animals (group H) receiving the radiotracer of high specific activity was 76,397 counts/kidney, whereas the uptake of the treated animals receiving the radiotracer of low specific activity (group I) was 74,949 counts/kidney. Seventy-one days after therapy, there was no significant difference in the renal 99mTc-DMSA uptake between groups G, H and I (51,344, 57,147 and 47,692 counts/kidney, respectively); 111 days after therapy, there was also no significant difference in the renal 99mTc-DMSA uptake between these three groups of mice.


So far, only three optimised BN analogues, DOTA-8-AOC-BN(7–14)NH2, AMBA (DO3A-CH2CO-8-aminooctanoyl-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) and DOTA-PESIN (DOTA-15-amino-4,7,10,13-tetraoxapentadecanoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2), have been evaluated for PRRT [2325]. These compounds were radiolabelled with the therapeutic radioisotopes 177Lu or 213Bi and showed anti-tumour effectiveness in mice with PC-3 xenografts. Regarding in vitro evaluation and biodistribution data, our 177Lu-DOTA-Lys-BN analogue showed pharmacokinetic properties which are comparable to those of the above-mentioned BN analogues, except for the higher tumour uptake and the better retention profile of AMBA and DOTA-PESIN. Therefore, we wanted to improve the radiotherapy relevant characteristics further by PEGylating 177Lu-DOTA-Lys-BN.

In vitro, time-dependent cell uptake and internalisation showed slower binding kinetics for the PEGylated BN analogue. These findings are in line with the results of PEGylating other biomolecules reported in the literature [31]. PEG is also reported to affect target association and dissociation rates of antibody fragments negatively [32]. These aspects may apply to our 177Lu-DOTA-PEG5k-Lys-BN and explain why binding affinity of this analogue in vitro was slightly reduced ( Additional file 1), the steady state was reached later, and the total cell binding was lower in comparison with that of the non-PEGylated counterpart.

Previously, we could confirm that PEGylation improves the stability of BN toward enzymatic degradation [26]. In the case of DOTA-Lys-BN, conjugation of PEG5k also led to a considerable increase in stability in vitro (Figure 2). The half-life (t 1/2) of 177Lu-DOTA-PEG5k-Lys-BN in human plasma was 5.6-fold higher in comparison with that of non-PEGylated 177Lu-DOTA-Lys-BN. In comparison to 177Lu-AMBA, which is more stable in human plasma (t 1/2 = 38.8 h) [23] than 177Lu-DOTA-PESIN (t 1/2 = 8.4 h) [25], the in vitro half-life of 177Lu-DOTA-Lys-BN in human plasma (t 1/2 = 28.8 h) was in the same range but was markedly higher with the PEGylated BN analogue (t 1/2 = 160.8 h).

The biodistribution data, in which 0.002 nmol of 177Lu-AMBA and 177Lu-DOTA-8-AOC-BN(7–14) (HPLC purified) was injected per mouse [23], and the data of 177Lu-DOTA-PESIN (0.2 nmol peptide) [25] were compared with our biodistribution data, in which 0.075 nmol of the 177Lu-labelled BN analogues were injected. This 0.075 nmol is the nearest possible approximation to the 0.002 nmol without HPLC purification, which is desired in clinics. In comparison with 177Lu-AMBA, our 177Lu-DOTA-Lys-BN showed an approximately fourfold lower kidney uptake 1 h p.i., whereas the kidney uptake of the 177Lu-DOTA-PEG5k-Lys-BN analogue was 2.3-fold lower at 1 h p.i. Both compounds showed a faster clearance from the kidneys within 24 h p.i. Kidney accumulation and washout of our 177Lu-DOTA-Lys-BN and 177Lu-DOTA-PEG5k-Lys-BN were comparable to those of 177Lu-DOTA-PESIN (3.8 ± 0.34%ID/g at 1 h p.i.), even though Gelofusine and polyglutamic acid were co-administered with 177Lu-DOTA-PESIN for the reduction of renal uptake [25]. Furthermore, the GI uptake was much lower with 177Lu-DOTA-Lys-BN and 177Lu-DOTA-PEG5k-Lys-BN at 1 and 24 h p.i. compared with that in 177Lu-AMBA (11.2%ID and 5.8% ID, respectively) and 177Lu-DOTA-8-AOC-BN(7–14) (9.7%ID and 1.7% ID, respectively) [23]. However, the significantly higher blood level at 1 h p.i. after PEGylation might cause higher bone marrow toxicity and could therefore be a potential drawback of PEGylation.

177Lu-DOTA-PEG5k-Lys-BN showed significantly higher tumour uptake at 1 h p.i. in comparison with the non-PEGylated counterpart. The higher enzymatic stability as well as the longer blood circulation may have compensated for the slower binding kinetics and the lower receptor affinity of DOTA-PEG5k-Lys-BN. In order to compare the cumulative radioactivity over 24 h of each conjugate in the tumour, the AUC value of 177Lu-DOTA-Lys-BN was arbitrarily set to 1. The comparison showed a relative AUC value of 1.6 (P < 0.0006) for 177Lu-DOTA-PEG5k-Lys-BN.

The second hypothesis that PEGylation prolongs the tumour retention was also proven. Even though PEGylation lowered the tumour washout only slightly between 1 and 24 h p.i., there was more 177Lu-DOTA-PEG5k-Lys-BN retained in the tumour between 0 and 24 h p.i. The extended tumour retention for the 177Lu-DOTA-PEG5k-Lys-BN might be explained by the improved enzymatic stability of the peptide derivative, and the extended retention might be due to the enhanced permeation and retention in the tumour. On the basis of the biodistribution data with 177Lu-AMBA [23] and 177Lu-DOTA-PESIN [25], both BN analogues showed higher tumour uptakes (6.35 ± 2.23% ID/g and 11.6 ± 1.4%ID/g at 1 h p.i., respectively) and better retention profiles than our 177Lu-labelled BN analogues. However, compared to 177Lu-DOTA-8-AOC-BN(7–14) [23] (2.84 ± 1.65% ID/g at 1 h p.i.), our 177Lu-DOTA-Lys-BN analogue showed a similar tumour uptake, but the uptake of 177Lu-DOTA-PEG5k-Lys-BN was higher. This comparison, however, must be looked at with due care because the study designs differ insofar as different peptide amounts were injected.

The third hypothesis, i.e. that PEGylation improves tumour-to-non-target ratios, could partially be confirmed. The tumour-to-non-target ratios were rather similar for both derivatives. However, in comparison with the non-PEGylated BN analogue, the 177Lu-DOTA-PEG5k-Lys-BN analogue exhibited a higher tumour uptake and a prolonged tumour retention which resulted in increased tumour-to-pancreas ratios at all time points and in higher tumour-to-liver and tumour-to-kidney ratios at 24 h p.i. (Figure 3).

Alongside PEGylation, the influence of the specific activity on biodistribution was evaluated. 177Lu-DOTA-PEG5k-Lys-BN injected at two different peptide amounts corresponding to the amount that was injected in the therapy studies (0.3 or 3.0 nmol, respectively) affected the uptake into receptor-expressing tissues. The amount of 0.3 nmol was selected to approximate the 0.22 nmol of the AMBA therapy study because these amounts of 0.3 nmol have proven to be the limit for high specific labelling, i.e. the labelling is reproducible without any loss in yield. The amount of 3.0 nmol however was selected because a preliminary study (data not presented) had suggested that peptide amounts in this range markedly reduce the uptake into non-target receptor positive tissues. In comparison with a low peptide amount, applying a high peptide amount resulted in a marked reduction in pancreas and colon uptake which would lower the risk of radiotoxic side effects induced by radionuclide therapy (Figure 4). However, the cumulative radioactivity in the tumour was significantly higher with a low peptide amount. The dosimetry showed that the absorbed dose into the tumour was 1.7-fold higher with the radiotracer of high specific activity, which would presumably indicate a higher anti-tumour effect. Furthermore, a lower accumulation in the kidneys within 24 h p.i. was observed with 177Lu-DOTA-PEG5k-Lys-BN at a low amount of peptide (Table 3), which would indicate a reduced risk of nephrotoxicity induced by radionuclide therapy. Thus, the incidence of BN-related toxicity after i.v. injection could be reduced using a low amount of peptide.

The radionuclide therapy studies (Table 1) showed a higher anti-tumour effectiveness with 177Lu-DOTA-PEG5k-Lys-BN (group D) compared with 177Lu-DOTA-Lys-BN (group F) (63% vs. 53% inhibition 3 weeks after the first dose, respectively; Figure 6). This is in accordance with the biodistribution data, which showed a higher tumour uptake and retention after PEGylation (Table 2). As comparative time point, we chose 3 weeks after the first dose, in order to evaluate the effectiveness of the different therapy protocols. This is the latest time point before several mice had to be euthanised upon fulfilling the endpoint criteria. Therefore, an interpretation after 3 weeks is not reliable since the groups represent only individual mice (Figures 5 and 6).

The therapy studies, in which the specific activity was varied (group C vs. group D), resulted in a markedly higher therapeutic efficiency when 177Lu-DOTA-PEG5k-Lys-BN was applied at high specific activity (63% vs. 36% inhibition 3 weeks after the first dose). The lower tumour accumulation of 177Lu-DOTA-PEG5k-Lys-BN of low specific activity resulted in a proportionally faster tumour growth. We could demonstrate that the reduced efficacy is not caused by the tumour growth-promoting effect of the higher peptide amount since unlabelled DOTA-PEG5k-Lys-BN (group B) did not induce tumour growth compared with the control group (Figure 5). These results are in line with previous observations reported in the literature [25]. The high specific therapy, as we have seen, was more efficient than the low specific, which is in accordance with the biodistribution studies which demonstrate that the uptake in GRPR-expressing tissues is highest for the lower peptide dose and is reduced with the higher peptide dose. This phenomenon is considered to be the result of partial saturation of receptors in the target tissues at higher peptide doses.

Furthermore, it can be assumed that an increase in specific activity would achieve at least the same therapeutic efficiency as low specific activity, but the dosage injected would be lower.

Preliminary therapy studies (Additional file 1: Figure S8), as expected, showed that the administration of two doses (2 × 20 MBq = 40 MBq) was more effective in tumour growth inhibition than application of a single dose (20 MBq). As shown with in vitro autoradiography (Additional file 1: Figure S9), there was no long-lasting down-regulation of BN2/GRP receptors in the tumour after treatment, which suggests that it is sensible to apply a multiple dosage. Therefore, two different two-dose regimens were evaluated in the current therapy studies. Applying the second dose at day 14 was chosen to match the AMBA therapy study. The preliminary study showed that the tumour started to grow after 14 days regardless of the second injection. Since the cause for this might have been that the tumour was already too large to respond to the treatment, the second application was introduced at day 7 in order to hit the tumour in an earlier state. The therapeutic efficiency was increased even further when the second dose of 177Lu-DOTA-PEG5k-Lys-BN (group E) was applied 7 days after the first dose instead of 14 days (73% vs. 63% inhibition at day 21) (group D).

Comparing our study with the therapy studies with 177Lu-AMBA [23], 177Lu-DOTA-PESIN [25] (2 × 28 MBq, 0.2 nmol) and 177Lu-DOTA-8-AOC-BN(7–14) [24], we found the tumour growth inhibition with our PEGylated BN analogue to be lower than with AMBA (approximately 73% vs. approximately 82%) but higher than with DOTA-PESIN (approximately 73% vs. approximately 45%) and roughly the same as with 177Lu-DOTA-8-AOC-BN(7–14) (approximately 73% vs. approximately 79%) 3 weeks after the first dose. However, such a comparison is not fully conclusive since these therapy studies differ in tumour size at the beginning of therapy, injected peptide amount, administered radiation dose and injection interval.

In order to assess the risk for nephrotoxicity related to radionuclide therapy, a rough dosimetric estimate for an adult male was performed based on the biodistribution, in which 0.3 or 3.0 nmol of the 177Lu-DOTA-PEG5k-Lys-BN analogue were applied. This estimate implies that an administration of approximately 2 GBq of either low or high specific 177Lu-DOTA-PEG5k-Lys-BN analogue would result in absorbed kidney doses of approximately 18.8 or 24.6 Gy, respectively. These doses would not exceed the acceptable safe limit of 23 to 27 Gy [33]. The administration of 2 GBq would supposedly be necessary to reach a tumour dose of 50 Gy (supposed that the absorbed dose into the pancreas corresponds to the tumour dose), which is needed for treatment as external beam radiation therapy and brachytherapy data suggest [3436]. A further step in the risk assessment was 99mTc-DMSA scintigraphy which showed that there was no kidney damage in the mice treated with high or low specific 177Lu-DOTA-PEG5k-Lys-BN analogue (group H and I) since there was no significant difference in renal 99mTc-DMSA uptake of control and treated mice. Besides, serum analysis confirmed the absence of renal toxicity (Additional file 1).


PEGylation, increasing the specific activity of the radiolabelled bombesin analogue and shortening the injection interval proved to be effective strategies to enhance the radiotherapeutic efficacy and to provide a favourable risk-profile at the same time. Tumour targeting was optimised and tumour retention was prolonged with the 177Lu-DOTA-PEG5k-Lys-BN analogue of high specific activity. The estimate of the absorbed doses for an adult male implied that the absorbed kidney doses would lie below the threshold of kidney damage. Taking the positive features into account, which have been observed in this study, we believe that PEGylation of small molecular weight radiopharmaceuticals is an efficient strategy to improve their potential for a successful application in targeted radionuclide therapy.



The authors thank Dr. Alexander Hohn, Mr. Alain Blanc and Ms. Olga Gasser for technical assistance. They also thank Ms. Elisbeth Rogg (Laboratory of Veterinary Medicine at the University of Zurich) for measuring plasma samples. This work was supported by a grant from the Swiss Cancer League Nr. KLS-02040-02-2007.

Authors’ Affiliations

Paul Scherrer Institute, Center for Radiopharmaceutical Sciences ETH-PSI-USZ
Department of Organic Chemistry, Vrije Universiteit Brussel
Department of Chemistry and Applied Biosciences


  1. Nagalla SR, Barry BJ, Falick AM, Gibson BW, Taylor JE, Dong JZ, Spindel ER: There are three distinct forms of bombesin: identification of [Leu13]bombesin, [Phe13]bombesin, and [Ser3, Arg10, Phe13]bombesin in the frog Bombina orientalis. J Biol Chem 1996, 271: 7731–7737. 10.1074/jbc.271.13.7731PubMedView ArticleGoogle Scholar
  2. Reubi JC, Wenger S, Schmuckli-Maurer J, Schär JC, Gugger M: Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[D-TYR6, beta-ALA11, PHE13, NLE14] bombesin(6–14). Clin Cancer Res 2002, 8: 1139–1146.PubMedGoogle Scholar
  3. Gugger M, Reubi JC: Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 1999, 155: 2067–2076. 10.1016/S0002-9440(10)65525-3PubMed CentralPubMedView ArticleGoogle Scholar
  4. Markwalder R, Reubi JC: Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999, 59: 1152–1159.PubMedGoogle Scholar
  5. Moody TW, Cuttitta F: Growth factor and peptide receptors in small cell lung cancer. Life Sci 1993, 52: 1161–1173. 10.1016/0024-3205(93)90098-NPubMedView ArticleGoogle Scholar
  6. Lambert B, Cybulla M, Weiner SM, Van De Wiele C, Ham H, Dierckx RA, Otte A: Renal toxicity after radionuclide therapy. Radiat Res 2004, 161: 607–611. 10.1667/RR3105PubMedView ArticleGoogle Scholar
  7. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O’Dorisio TM, Valkema R, Bodei L, Chinol M, Mäcke HR, Krenning EP: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005,46(Suppl 1):62S-66S.PubMedGoogle Scholar
  8. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP: Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. J Nucl Med 2005,46(Suppl 1):83S-91S.PubMedGoogle Scholar
  9. Hoffman TJ, Gali H, Smith CJ, Sieckman GL, Hayes DL, Owen NK, Volkert WA: Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003, 44: 823–831.PubMedGoogle Scholar
  10. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, Mäcke HR: Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004, 64: 6707–6715. 10.1158/0008-5472.CAN-03-3845PubMedView ArticleGoogle Scholar
  11. Schroeder RP, Müller C, Reneman S, Melis ML, Breeman WA, de Blois E, Bangma CH, Krenning EP, van Weerden WM, de Jong M: A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging 2010, 37: 1386–1396. 10.1007/s00259-010-1388-2PubMed CentralPubMedView ArticleGoogle Scholar
  12. Smith CJ, Volkert WA, Hoffman TJ: Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol 2003, 30: 861–868. 10.1016/S0969-8051(03)00116-1PubMedView ArticleGoogle Scholar
  13. Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, Maina T: [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003, 30: 247–258. 10.1007/s00259-002-1040-xPubMedView ArticleGoogle Scholar
  14. Garcia Garayoa E, Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwe DA, Schibli R, Schubiger PA: Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core. Bioconjug Chem 2008, 19: 2409–2416. 10.1021/bc800262mPubMedView ArticleGoogle Scholar
  15. Schweinsberg C, Maes V, Brans L, Bläuenstein P, Tourwe DA, Schubiger PA, Schibli R, Garcia Garayoa E: Novel glycated [99mTc(CO)3]-labeled bombesin analogues for improved targeting of gastrin-releasing peptide receptor-positive tumors. Bioconjug Chem 2008, 19: 2432–2439. 10.1021/bc800319gPubMedView ArticleGoogle Scholar
  16. Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, Lehmann L, Schubiger PA, Ametamey SM, Dinkelborg L, Srinivasan A, Borkowski S: 18 F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med 2011, 52: 270–278. 10.2967/jnumed.110.081620PubMedView ArticleGoogle Scholar
  17. Mu L, Honer M, Becaud J, Martic M, Schubiger PA, Ametamey SM, Stellfeld T, Graham K, Borkowski S, Lehmann L, Dinkelborg L, Srinivasan A: In vitro and in vivo characterization of novel 18 F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem 2010, 21: 1864–1871. 10.1021/bc100222uPubMedView ArticleGoogle Scholar
  18. Höhne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, Stellfeld T, Borkowski S, Berndorff D, Klar U, Voigtmann U, Cyr JE, Friebe M, Dinkelborg L, Srinivasan A: Synthesis, 18 F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem 2008, 19: 1871–1879. 10.1021/bc800157hPubMedView ArticleGoogle Scholar
  19. Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M: GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68 Ga-labeled bombesin(6–14) analog. J Nucl Med 2005, 46: 691–699.PubMedGoogle Scholar
  20. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Mäcke HR, Eisenhut M, Strauss LG: 68 Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18 F-FDG. J Nucl Med 2007, 48: 1245–1250. 10.2967/jnumed.106.038091PubMedView ArticleGoogle Scholar
  21. Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE: In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med 2011, 52: 470–477. 10.2967/jnumed.110.082826PubMed CentralPubMedView ArticleGoogle Scholar
  22. Schroeder RP, van Weerden WM, Bangma C, Krenning EP, de Jong M: Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods 2009, 48: 200–204. 10.1016/j.ymeth.2009.04.002PubMedView ArticleGoogle Scholar
  23. Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, Thomas R, Eaton SM, Bogdan NJ, Arunachalam T, Reubi JC, Raju N, Metcalfe EC, Lattuada L, Linder KE, Swenson RE, Tweedle MF, Nunn AD: 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006, 47: 1144–1152.PubMedGoogle Scholar
  24. Johnson CV, Shelton T, Smith CJ, Ma L, Perry MC, Volkert WA, Hoffman TJ: Evaluation of combined 177Lu-DOTA-8-AOC-BBN(7–14)NH2 GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm 2006, 21: 155–166. 10.1089/cbr.2006.21.155PubMed CentralPubMedView ArticleGoogle Scholar
  25. Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, Provencher-Bolliger A, Reubi JC, Mäcke HR: Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res 2011, 71: 1009–1018. 10.1158/0008-5472.CAN-10-1186PubMedView ArticleGoogle Scholar
  26. Däpp S, García-Garayoa E, Maes V, Brans L, Tourwé DA, Müller C, Schibli R: PEGylation of 99mTc-labeled bombesin analogues improves their pharmacokinetic properties. Nucl Med Biol 2011, 38: 997–1009. 10.1016/j.nucmedbio.2011.02.014PubMedView ArticleGoogle Scholar
  27. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP: Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008, 26: 2124–2130. 10.1200/JCO.2007.15.2553PubMedView ArticleGoogle Scholar
  28. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP: Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006, 36: 147–156. 10.1053/j.semnuclmed.2006.01.001PubMedView ArticleGoogle Scholar
  29. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP: [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001, 28: 1319–1325. 10.1007/s002590100574PubMedView ArticleGoogle Scholar
  30. Larsson E, Strand S-E, Ljungberg M, Jönsson B-A: Mouse S-factors based on Monte Carlo simulations in the anatomical realistic Moby phantom for internal dosimetry. Cancer Biother Radiopharm 2007, 22: 438–442. 10.1089/cbr.2006.320PubMedView ArticleGoogle Scholar
  31. Harris JM, Chess RB: Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2: 214–221. 10.1038/nrd1033PubMedView ArticleGoogle Scholar
  32. Kubetzko S, Sarkar CA, Pluckthun A: Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 2005, 68: 1439–1454. 10.1124/mol.105.014910PubMedView ArticleGoogle Scholar
  33. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, Baio SM, Sansovini M, Paganelli G: Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008, 35: 1847–1856. 10.1007/s00259-008-0778-1PubMedView ArticleGoogle Scholar
  34. Isacsson U, Nilsson K, Asplund S, Morhed E, Montelius A, Turesson I: A method to separate the rectum from the prostate during proton beam radiotherapy of prostate cancer patients. Acta Oncol 2010, 49: 500–505. 10.3109/02841861003745535PubMedView ArticleGoogle Scholar
  35. Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach Iii M, Gottschalk AR: Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 2012, 82: 228–234. 10.1016/j.ijrobp.2010.10.026PubMedView ArticleGoogle Scholar
  36. Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, Gustafson G: High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Rad Oncol Biol Phys 2011, 81: 1286–1292. 10.1016/j.ijrobp.2010.10.015View ArticleGoogle Scholar
  37. Garcia Garayoa E, Rüegg D, Bläuenstein P, Zwimpfer M, Khan IU, Maes V, Beck-Sickinger AG, Tourwé DA, Schubiger PA: Chemical and biological characterization of new Re(CO)3/[99mTc](CO)3 bombesin analogues. Nucl Med Biol 2007, 34: 7–28.View ArticleGoogle Scholar
  38. Pillarsetty N, Cai S, Ageyeva L, Finn RD, Blasberg RG: Synthesis and evaluation of [18 F] labeled pyrimidine nucleosides for positron emission tomography imaging of herpes simplex virus 1 thymidine kinase gene expression. J Med Chem 2006, 49: 5377–5381. 10.1021/jm0512847PubMedView ArticleGoogle Scholar
  39. La Bella R, Garcia-Garayoa E, Bahler M, Blauenstein P, Schibli R, Conrath P, Tourwé D, Schubiger PA: A 99mTc(I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjug Chem. 2002, 13: 599–604. 10.1021/bc015571aPubMedView ArticleGoogle Scholar


© Däpp et al.; licensee Springer. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.